RayzeBio is a biopharmaceutical company focused on developing radiopharmaceutical medicines to defeat cancer. They have a diverse portfolio of radiopharmaceutical drug candidates, ranging from discovery to late-stage clinical programs.

RayzeBio

RayzeBio Inc. is now part of Bristol Myers Squibb. Follow our progress delivering breakthrough therapies through our differentiated radiopharmaceutical platform @Bristol Myers Squibb or www.bms.com

LifeSci Venture Partners

Logos Capital

Vivo Capital

Samsara BioCapital

OrbiMed

Perceptive Advisors

Redmile Group

venBio Partners

Versant Ventures

Ally Bridge Group

Laurion Capital Management

Wellington Management

Sands Capital Ventures

Sofinnova Investments

Soleus Capital

Viking Global Investors

As of today, RayzeBio, Inc. is officially part of Bristol Myers Squibb! We are excited to continue our mission and look forward to delivering breakthrough therapies through our differentiated radiopharmaceutical platform as part of BMS. Follow our progress Bristol Myers Squibb

We are excited to announce our proposed acquisition by Bristol Myers Squibb. Our leading position in radiopharmaceutical therapeutics coupled with the broad and deep expertise of BMS in oncology allows us to work together to bring forth this next wave of innovation in cancer therapy for patients. 

https://lnkd.in/gTEy-mC4

Look forward to catching up in NY, London, or Miami this month at the Truist, Jefferies London, or Evercore Healthcare conference

https://lnkd.in/gxaTaMTE

COM:RAYZEBIO

RayzeBio